Pre-earnings brief
Reports
Mon, Nov 9, 2026
Est. EPS
—
Est. revenue
—
Implied move
±14.4%
EPS beat rate
75%
Aurinia Pharmaceuticals Inc. is a biotechnology company focused on developing therapies for kidney diseases. With a market cap of $2 billion, it operates in the health care sector, which is increasingly important as the demand for innovative treatments continues to grow.
Last quarter
In Q2 2026, Aurinia reported an EPS of $0.28, significantly beating estimates by 55.56%. The stock reacted positively, gaining 6.19% the following day.
EPS beat streak
4Q
EPS beat rate
75%
Avg EPS surprise
+144.50%
Avg 1-day reaction
+1.76%
Investors are cautiously optimistic ahead of the earnings report, given Aurinia's recent strong performance. However, the lack of analyst estimates creates uncertainty.
Bull case
If Aurinia continues its trend of beating EPS estimates, it could signal strong operational performance and lead to further stock price appreciation.
Bear case
On the other hand, any signs of revenue stagnation or failure to meet expectations could lead to a negative market reaction, especially given the high implied volatility.
The print will turn on these.
Q1
What will the EPS be for Q3-2026?
Given Aurinia's strong EPS surprises in recent quarters, this number will be crucial for investor confidence.
Q2
How is revenue trending compared to previous quarters?
Investors will closely watch revenue growth to assess the company's market position and demand for its products.
—
Est. EPS
$1.46
Est. Rev
$5.2B
Impl. Move
±12.1%
Why consensus could be wrong
The Street may be underestimating Aurinia's ability to sustain its recent earnings momentum, particularly given the company's strong track record of beating EPS estimates.
Supporting evidence
Aurinia has consistently surprised to the upside with a 75% EPS beat rate over the last eight quarters.
The options market is pricing in a larger move than historical averages, suggesting heightened expectations.
Recent performance trends indicate a strong demand for its products, which may not be fully reflected in current analyst estimates.
Key risk
If the EPS comes in below $0.20, it could significantly undermine the bullish narrative.
Pre-commit to what would confirm each case.
The market is debating the sustainability of Aurinia's recent earnings growth and its ability to maintain revenue momentum.
Bull confirmed if
An EPS of $0.30 or higher would confirm the bull case, indicating continued strong performance.
Bear confirmed if
An EPS below $0.20 would confirm the bear case, suggesting potential issues with profitability.
What the market is pricing for the move.
Implied Move
±14.375%
Historical Avg
±5.5%
The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.
Options are pricing ±14.4% while AUPH has averaged ±5.5% over the last 8 prints — setup is pricing rich.
ATM IV
0.5%
30d HV
22.7%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 11 of 30 (37%)
This setup has occurred 30 times across Health Care in the last 2 years. 19 of 30 (63%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 3.7%, with a raw directional average of -0.1% (roughly flat historical bias).
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Aurinia beats expectations, history suggests a positive reaction with an average 1-day move of +2.83%, confirming strong operational health.
In line / cautious
If results are in line but management's commentary is cautious, the stock may react neutrally as investors weigh future growth prospects.
Miss
A miss could lead to a decline, with history suggesting an average 1-day drop of -1.44%, reflecting disappointment in performance.
The lines on the call that would change the story.